8.11
Schlusskurs vom Vortag:
$7.52
Offen:
$7.52
24-Stunden-Volumen:
298.95K
Relative Volume:
0.78
Marktkapitalisierung:
$478.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.1978
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+8.86%
1M Leistung:
+5.74%
6M Leistung:
-22.84%
1J Leistung:
-57.54%
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CGEM
Cullinan Therapeutics Inc
|
8.11 | 439.66M | 0 | -153.16M | -134.48M | -3.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-11 | Fortgesetzt | Stifel | Buy |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-05-01 | Eingeleitet | Stifel | Buy |
2024-04-15 | Eingeleitet | William Blair | Outperform |
2024-02-15 | Eingeleitet | Wedbush | Outperform |
2023-06-15 | Eingeleitet | TD Cowen | Outperform |
2022-11-21 | Eingeleitet | BTIG Research | Buy |
2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
What drives Cullinan Therapeutics Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com
Breakthrough Lung Cancer Treatment: Zipalertinib Trial Results Reveal New Hope for Hard-to-Treat EGFR Mutations - Stock Titan
Is Cullinan Therapeutics Inc. a good long term investmentFree Predictions - Autocar Professional
What analysts say about Cullinan Therapeutics Inc. stockExplosive market performance - jammulinksnews.com
Cullinan Therapeutics Inc. Stock Analysis and ForecastExceptional stock performance - jammulinksnews.com
Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha
How Cullinan Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - Newser
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser
What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Disc Medicine Appoints Nadim Ahmed To Board - citybiz
Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times
We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia
Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener
Assenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC - insights.citeline.com
Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World
Cullinan Management Holds Annual Stockholders Meeting - TipRanks
Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech
California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus
Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus
Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
The week in pharma: action, reaction and insight – week to June 6 - The Pharma Letter
Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com
Transcript : Cullinan Therapeutics, Inc.Special Call - MarketScreener
Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa
Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):